-
2024-514068-14-00
9
2021-10-12
leptomeningeal disease
-
2023-509357-31-00
1
2021-06-01
Multiple Sclerosis (MS)
-
2023-507202-14-00
7
2021-04-29
Upper limb spasticity after stroke or traumatic brain injury
-
2023-509863-26-00
11
2021-04-29
Liver cirrhosis
-
2024-512671-12-00
10
2021-03-05
Unresectable head and neck squamous cell carcinoma, metastatic head an
-
2024-510616-73-00
5
2020-12-16
newly diagnosed WHO grade 2 or 3 glioma
-
2024-513950-32-00
4
2020-12-15
Intermediate stage hepatocellular carcinoma (HCC)
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2024-510841-32-00
1
2020-05-27
Advanced or metastatic carcinomas after previous immune checkpoint blo
-
2023-506914-32-00
4
2020-05-05
Pan tumor
-
2024-512654-19-00
5
2020-03-06
Sickle Cell Disease
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2024-512894-29-00
7
2019-11-15
Prostate Cancer
-
2023-507689-26-00
5
2019-10-07
Histologically or cytologically confirmed Locoregional Hepatocellular
-
2024-512321-84-00
5
2019-10-02
Patients after HSCT suffering from new or reactivated CMV or EBV or Ad
-
2024-510964-21-00
9
2019-09-12
Glioblastoma
-
2023-506131-15-00
5
2019-09-10
Juvenile Idiopathic Arthritis
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma